吉岡靖雄

Profile

2004年大阪大学大学院薬学研究科修了、博士（薬学）号取得。国立医薬品食品研究所、大阪大学臨床医工学融合研究教育センターを経て2012年より大阪大学大学院薬学研究科准教授。2015年より現職。

Publication

(1) Inflammatory mediators of mRNA vaccine-induced adverse reactions in mice. Honda K. et. al. Mol Ther. (2026)S1525-0016(26)00023-7.
(2) mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection. Kunishima Y. et. al. Mol Ther Nucleic Acids. (2025)36(4):102731.
(3) Modulating Immunogenicity and Reactogenicity in mRNA-Lipid Nanoparticle Vaccines through Lipid Component Optimization. Kawaguchi Y. et. al. ACS Nano. (2025)19(30):27977-28001.
(4) Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity. Hashimoto S. et. al. Mucosal Immunol. (2025)S1933-0219(25)00032-7.
(5) Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Kawai A. et. al. Mol Ther. (2025)33(2):529-547.
(6) Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction. Kawahara E. et. al. NPJ Vaccines. (2024)9(1):187.
(7) Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen. Kawai A. et. al. ACS Nano. (2024)18(26):16589-16609.
(8) Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses. Kawai A. et. al. J Clin Invest. (2023)133(23):e166827.
(9) Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models. Morita M. et. al. Proc Natl Acad Sci USA. (2023)120(3):e2213317120.
(10) SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression. Hashimoto R. et. al. Sci Adv. (2022)8(38):eabo6783.
(11) Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants. Kitagawa S. et. al. NPJ Vaccines. (2022)7(1):115.
(12) Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice. Matsuda T. et. al. iScience. (2022)25(11):105324.
(13) The potential of neuraminidase as an antigen for nasal vaccines to increase cross-protection against influenza viruses. Kawai A. et. al. J Virol. (2021)95(20):e0118021.
(14) Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza. Shibuya M. et. al. iScience. (2021)24(10):103131.
(15) Neutrophil-Mediated Lung Injury Both via TLR2-Dependent Production of IL-1α and IL-12 p40, and TLR2-Independent CARDS Toxin after Mycoplasma pneumoniae Infection in Mice. Tamiya S. et. al. Microbiol Spectr. (2021)9(3):e0158821.
(16) Murine cross-reactive non-neutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice. Shibuya M. et. al. J Virol. (2020)94(12):e00323-20.